Third FDA orphan designation for LP-284; Sixth overall for Lantern’s A.I.-driven precision oncology pipeline Orphan designation expands LP-284's potential for an estimated ~96,000 global annual soft ...
(MENAFN- Investor Brand Network) Lantern Pharma (NASDAQ: LTRN) announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to LP-284 for the treatment of soft tissue ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results